Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.
Hong Kong Med J. 2013 Feb;19(1):20-6.
To investigate the diagnostic performance and safety of endobronchial ultrasound-guided transbronchial needle aspiration in patients presenting with radiological features of lung cancer.
Prospective case series.
University teaching hospital, Hong Kong.
Consecutive patients with mediastinal or hilar abnormalities suspected of or confirmed as having lung cancer underwent endobronchial ultrasound-guided transbronchial needle aspiration and presented between August 2006 and December 2010.
Diagnostic performance (including sensitivity, specificity, negative predictive value and accuracy), procedural complications, and tissue adequacy for molecular profiling.
A total of 269 procedures were performed in 259 patients, with malignancy confirmed in 210 (81%) of them. In the whole cohort with confirmed or suspected lung cancer, the overall sensitivity, specificity, negative predictive value, and accuracy of endobronchial ultrasound-guided transbronchial needle aspiration were 87%, 100%, 74%, and 91%, respectively. Among 42 patients with tumour samples sent for mutation tests (epidermal growth factor receptor and/or anaplastic lymphoma kinase), 40 (95%) were found to be adequate. No complication or mortality ensued from these procedures.
Endobronchial ultrasound-guided transbronchial needle aspiration is highly effective in determining the diagnosis and lymph node staging in patients with lung cancer. In combination with its excellent safety profile, it should be considered a frontline diagnostic test for patients presenting with mediastinal abnormalities suspicious of lung cancer.
研究支气管内超声引导经支气管针吸活检术(EBUS-TBNA)在影像学表现为肺癌的患者中的诊断性能和安全性。
前瞻性病例系列研究。
香港一所大学教学医院。
2006 年 8 月至 2010 年 12 月期间,连续就诊于纵隔或肺门异常,疑诊或确诊为肺癌的患者,接受了 EBUS-TBNA,并符合纳入标准。
诊断性能(包括敏感性、特异性、阴性预测值和准确性)、操作并发症和用于分子分析的组织充分性。
在 259 例确诊或疑似肺癌的患者中,共进行了 269 次操作,其中 210 例(81%)患者的恶性肿瘤得到证实。在整个确诊或疑似肺癌的队列中,EBUS-TBNA 的总体敏感性、特异性、阴性预测值和准确性分别为 87%、100%、74%和 91%。在 42 例送检肿瘤样本进行突变检测(表皮生长因子受体和/或间变性淋巴瘤激酶)的患者中,40 例(95%)的样本足够。这些操作没有导致任何并发症或死亡。
EBUS-TBNA 对于确定肺癌患者的诊断和淋巴结分期非常有效。鉴于其出色的安全性,它应被视为纵隔异常疑似肺癌患者的一线诊断性检查。